T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Pure Cycle
PCYO
$273M
| $191K | ﹤0.01% |
22,785
-110
| -0.5% | -$1.13K |
|
|
ACR
2552
ACRES Commercial Realty
ACR
$101M
| $190K | ﹤0.01% |
23,265
| – | – |
|
2553
Olema Pharmaceuticals
OLMA
$920M
| $190K | ﹤0.01% |
68,500
| – | – |
|
2554
Beazer Homes USA
BZH
$874M
| $189K | ﹤0.01% |
19,526
-15,022
| -43% | -$206K |
|
2555
IonQ
IONQ
$18.2B
| $189K | ﹤0.01% |
37,104
+12,467
| +51% | +$69.1K |
|
|
NPKI
2556
NPK International
NPKI
$1.18B
| $189K | ﹤0.01% |
74,733
+5,772
| +8% | +$17K |
|
2557
Commercial Vehicle Group
CVGI
$130M
| $188K | ﹤0.01% |
41,600
+4,800
| +13% | +$30.7K |
|
2558
Community Health Systems
CYH
$419M
| $188K | ﹤0.01% |
87,298
+28,007
| +47% | +$92.8K |
|
2559
Groupon
GRPN
$894M
| $188K | ﹤0.01% |
23,535
+5,146
| +28% | +$56K |
|
2560
Bionano Genomics
BNGO
$13.5M
| $187K | ﹤0.01% |
170
+29
| +21% | +$38.3K |
|
2561
Crescent Energy
CRGY
$3.93B
| $187K | ﹤0.01% |
13,865
+2,035
| +17% | +$29.8K |
|
|
ENG
2562
DELISTED
ENGlobal Corp
ENG
| $187K | ﹤0.01% |
18,518
-159
| -0.9% | -$1.79K |
|
|
AVYA
2563
DELISTED
Avaya Holdings Corp. Common Stock
AVYA
| $187K | ﹤0.01% |
117,130
+68,048
| +139% | +$108K |
|
2564
EVgo
EVGO
$519M
| $186K | ﹤0.01% |
23,426
+4,040
| +21% | +$35.2K |
|
|
TDAY
2565
USA Today Co
TDAY
$1B
| $186K | ﹤0.01% |
120,996
+28,921
| +31% | +$70.2K |
|
2566
Mitek Systems
MITK
$853M
| $185K | ﹤0.01% |
20,189
+2,544
| +14% | +$25.5K |
|
|
CMAX
2567
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $185K | ﹤0.01% |
869
+119
| +16% | +$24K |
|
2568
Aldeyra Therapeutics
ALDX
$86.9M
| $184K | ﹤0.01% |
34,387
-10,923
| -24% | -$65.5K |
|
|
ESPR
2569
DELISTED
Esperion Therapeutics
ESPR
| $183K | ﹤0.01% |
27,227
+9,408
| +53% | +$64.6K |
|
2570
Veritone
VERI
$139M
| $182K | ﹤0.01% |
32,184
+8,708
| +37% | +$61.2K |
|
|
ZIMV
2571
DELISTED
ZimVie
ZIMV
| $182K | ﹤0.01% |
18,394
-4,114
| -18% | -$66.4K |
|
2572
Vera Bradley
VRA
$94.7M
| $181K | ﹤0.01% |
60,100
+14,900
| +33% | +$60K |
|
|
TAST
2573
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $181K | ﹤0.01% |
110,890
+19,200
| +21% | +$40.6K |
|
2574
Global Net Lease
GNL
$1.9B
| $180K | ﹤0.01% |
+16,823
| New | +$234K |
|
2575
NovaGold Resources
NG
$3.4B
| $180K | ﹤0.01% |
38,258
+15,376
| +67% | +$71.2K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.